Mitigation of Anti-Drug Antibodies

Selecta Biosciences is advancing therapies based on its proprietary Synthetic Vaccine Particle (SVP™) platform to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) that can be formed in response to life-sustaining drugs.  The Company’s first programs in SVP for immune tolerance are focused on gout and gene therapy.

Click here to learn more about our Gout program
Click here to learn more about our Gene Therapy program

mitigation

Back to Top